

REPORT TO THE LEGISLATURE
Pursuant to P.A. 268 of
2016 Article V, Section 807
Hepatitis C treatment Report
4th Qtr-FY17

Section 807: The funds appropriated in part 1 for Hepatitis C treatment shall be used only to purchase specialty medication for Hepatitis C treatment in the prison population. In addition to the above appropriation, any rebates received from the medications used shall be used only to purchase specialty medication for Hepatitis C treatment. On a quarterly basis, the department shall issue a report to the senate and house appropriations subcommittees on corrections, the senate and house fiscal agencies, and the legislative corrections ombudsman, showing for the previous 4 quarters the total amount spent on specialty medication for the treatment of Hepatitis C, the number of prisoners that were treated, the amount of any rebates that were received from the purchase of specialty medication, and what outstanding rebates are expected to be received.

QTR	# of Prisoners that started treatment during QTR	Total # of prisoners in Treatment during QTR	# of Prisoners that completed treatment during QTR	Total expenditures during QTR	Total rebate rec'd	Total rebate expected
1st qtr 2017	76	182	111	\$ 5,165,083	\$ -	\$ -
2nd qtr 2017	97	167	85	\$ 3,398,062	\$ -	\$ -
3rd qtr 2017	59	125	78	\$ 3,369,859	\$ -	\$ -
4th qtr 2017	44	105	67	\$ 2,775,875	\$ -	\$ -